WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
VeriSIM Life | May 30, 2022
VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain www.totalbrain.com, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological disorders.
The partnership will pioneer the integration of Total Bra...
Gator Bio | September 15, 2021
Gator Bio, Inc. announced today the launch of the GatorPlus, a next generation biolayer interferometry (BLI) instrument and two new biosensor products, Gator™ Flex SA Kit and Gator™ AAVX probe. The GatorPlus adds to the currently available GatorPrime instrument; and the new Gator™ Flex SA Kit and Gator™ AAVX probe expand the off the shelf biosensor portfolio to 14 products for the North America market. Gator Bio also offers on demand custom biosensors for specific applica...
INDUSTRIAL IMPACT, MEDICAL
Accesswire | March 24, 2023
Moderna, Inc. a biotechnology company pioneering messenger RNA therapeutics and vaccines, and Generation Bio Co. a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that the two companies have entered into a strategic collaboration to combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform. The collaboration aims to expand the application ...
Sirona Biochem Corp. | November 24, 2022
Sirona Biochem Corp. announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals have signed an expanded, international partnership agreement to collaborate on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment in both animal and human health. The agreement adds human health to the partnership as a result of new licencing opportunities currently in due diligence.
Wanbang and Sirona initially signed a licensing agreement for TFC-039, w...
CELL AND GENE THERAPY
CELL AND GENE THERAPY, INDUSTRIAL IMPACT
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE